Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery: primary…
- Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02688608).
- Pembrolizumab in Combination With CRT for LA-SCCHN: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Combination With CRT for LA-SCCHN: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02586207).
- Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02964559).
- Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02267603).
- Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02882282).
- Pembrolizumab in Treating Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02337686).
- Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy:…
- Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma: primary endpoint results, effect estimate with confidence interval,…
- Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Pemetrexed Plus Gemcitabine in Renal Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed Plus Gemcitabine in Renal Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00491075).
- Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pento & tBUIndependent statistical analysis of Phase II Trial of Pentostatin and Targeted Busulfan: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00496340).
- Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- PEPIIndependent statistical analysis of Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00578864).
- Peptide Vaccination for Patients at High Risk for Recurrent Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Peptide Vaccination for Patients at High Risk for Recurrent Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00059475).
- Perampanel in Seizure Patients With Primary Glial Brain Tumors: Complete Statistical AnalysisIndependent statistical analysis of Perampanel in Seizure Patients With Primary Glial Brain Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02363933).
- PERTINENCEIndependent statistical analysis of Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PERUSEIndependent statistical analysis of A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer: primary…
- PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01205646).
- PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PETACC-3An independent statistical analysis of PETACC-3, a randomized phase 3 trial evaluating fluorouracil and leucovorin with or without irinotecan following surgery for stage III colorectal cancer.
- PETACC-6Independent statistical analysis of PETACC-6, a phase 3 randomized trial evaluating capecitabine with or without oxaliplatin after chemoradiation and before surgery in locally advanced rectal cancer. Includes trial design, endpoints, statistical methodology,…
- PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine: Complete Statistical AnalysisIndependent statistical analysis of PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03685591).
- Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00280735).
- Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo: Complete Statistical AnalysisIndependent statistical analysis of Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo: primary endpoint results, effect estimate with confidence interval, sample-size…
- Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00590902).
- Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pharmacokinetics and Hepatic Safety of EGCG: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics and Hepatic Safety of EGCG: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04177693).
- Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (MT-3724_NHL_003): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003): primary endpoint results, effect…